Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5 results about "Pulmonary tumor" patented technology

Lung Tumors. Lung cancer is considered a very life-threatening cancer and one of the most difficult to treat, because of its tendency to spread, or metastasize, very early after it forms. The lung also is a very common location for tumor metastasis from other parts of the body.

A recombinant adenovirus vector tumor vaccine and a preparation method and application thereof

PendingCN122146786AGenetic material ingredientsOncogene translation productsNasal cavityTherapeutic effect
The application discloses a recombinant adenovirus vector tumor vaccine and a preparation method and application thereof, wherein the antigen coded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of more than two antigen peptide epitopes of KRAS protein. The recombinant adenovirus vector tumor vaccine of the application codes multiple KRAS tumor-specific antigen peptides, and has a good killing effect on KRAS mutation-driven tumors, especially lung tumors. The vaccine can be inhaled in a form of atomization, injected into muscles first and then inhaled in a form of atomization, inhaled in a form of atomization first and then injected into muscles, injected into muscles, or simultaneously injected into muscles and administered in a form of atomization. After atomization, the vaccine can be inhaled through a nasal cavity or an oral cavity to reach the lungs, generate an anti-tumor protective immune response on the respiratory tract, the lungs and the whole body, and enhance the utilization rate and the treatment effect of the vaccine.
Owner:BRITIE BIOTECH CO LTD

Anti-microbial antibody signatures related to lung tumors and uses thereof

PendingUS20260194524A1Ct screeningBenign tumours
The present invention relates anti-microbial antibody signatures related to lung tumors, including benign tumors and adenocarcinomas. Disclosed herein are antibody panels comprising antigens from bacteria and / or viruses for use in early and accurate diagnosis of lung cancer and for reducing false positive lung carcinoma diagnoses from CT screening.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Application of leech dredging network preparation in preparation of anti-tumor drugs

The application belongs to the field of traditional Chinese medicines, and particularly discloses application of a leech dredging collaterals preparation in preparation of an anti-tumor medicine. The leech dredging collaterals preparation is prepared from four raw medicinal materials of astragalus, ligusticum wallichii, leech and salvia miltiorrhiza, and has the effects of tonifying qi and activating blood and dredging qi and collaterals. Pharmacodynamic studies show that the leech dredging collaterals preparation has the effects of inhibiting growth of liver tumors and lung tumors, is safe and has a good effect, expands the clinical application range of the leech dredging collaterals preparation, and has a good popularization and application prospect.
Owner:LUNAN PHARMA GROUP CORPORATION

Quantitative imaging biomarker for lung cancer

PendingUS20260141533A1Image enhancementImage analysisComputed tomographyPulmonary tumor
In one or more implementations, systems, methods and computer implemented processes are provided that are directed to a method of treating a subject with a lung tumor, the method comprising: obtaining computed tomography (CT) image slices of the subject, wherein the CT image slices comprise images of the lung tumor. In a further implementation, the systems, methods and computer implemented processes are directed to identifying a first CT image slice where the lung tumor has a largest diameter among the CT image slices; and determining intensity-skewness of the lung tumor on the first CT image slice. In a further implementation, the systems, methods and computer implemented processes are directed to treating the subject with surgery, chemotherapy and / or radiotherapy, if the intensity-skewness is no greater than-1.5.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK